| 000 | 01290 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250517234311.0 | ||
| 264 | 0 | _c20200219 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a1875-6190 | ||
| 024 | 7 |
_a10.2174/1570159X16666180830100754 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlborghetti, Marika | |
| 245 | 0 | 0 |
_aDifferent Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. _h[electronic resource] |
| 260 |
_bCurrent neuropharmacology _c2019 |
||
| 300 |
_a861-873 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAlanine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzylamines _xtherapeutic use |
| 650 | 0 | 4 |
_aDopamine Agents _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndans _xtherapeutic use |
| 650 | 0 | 4 |
_aLevodopa _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMonoamine Oxidase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aSelegiline _xtherapeutic use |
| 700 | 1 | _aNicoletti, Ferdinando | |
| 773 | 0 |
_tCurrent neuropharmacology _gvol. 17 _gno. 9 _gp. 861-873 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/1570159X16666180830100754 _zAvailable from publisher's website |
| 999 |
_c28781370 _d28781370 |
||